Latest news with #ICONplc
Business Wire
23-07-2025
- Business
- Business Wire
ICON Announces Results of Annual General Meeting
DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: ** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 39,900 employees in 95 locations in 55 countries as at June 30, 2025. For further information about ICON, visit: This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at ICON/ICLR-F
Yahoo
16-07-2025
- Business
- Yahoo
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN, July 16, 2025--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies. The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, operational excellence, and customer satisfaction. Key highlights from the report include: Sponsor satisfaction: For phase 1 research, ICON outperformed all other large CROs claiming the highest overall sponsor satisfaction score of 7.4 on a scale of 1-10. Outstanding operational metrics: ICON outperformed the average performance score of other large CROs in all 17 operational metrics, with a considerable lead differential in 14. These metrics are grouped into three categories of critical service capabilities including delivery metrics (such as adhering to project timelines), staff characteristics (like therapeutic expertise), and accessibility metrics (clinic availability, for example). Robust brand strength: Across the four brand strength performance metrics of familiarity, leadership, reported recent use, and preference, ICON was the only large CRO to improve its scores across the board compared to ISR's 2024 iteration of this research, with the largest gains in leadership and preference. Consistency of excellence: For six consecutive years, ICON has outperformed the weighted average performance scores of the other large CROs in phase 1 clinical trials, demonstrating sustained excellence and reliability. "ICON's strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally," said Steve Cutler, CEO. "Our consistent leadership in phase 1 clinical trials is a testament to our ability to meet and exceed client expectations, deliver high-quality outcomes, and advance breakthroughs in early-phase development." The benchmarking report used a rigorous methodology to ensure results reflected ICON's true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance of role and responsibility, and mandated a recent interaction with a CRO. The survey data was collected in Q4 2024. For more information, please visit About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: About ISR Market Research: ISR utilises primary research methodologies to offer novel insights into the drug development industry. As an independent market research partner focusing on the life sciences space, ISR helps clients make data-informed decisions with specificity and precision that generalist firms can't match. ISR's analysts are industry experts in their own right with over 15 years of experience in this niche. They also diligently curate membership for ISR's Life Science Panel of respondents. Panel members are from a wide spectrum of geographies and job levels across a variety of roles & responsibilities, and their valuable experiential data informs both ISR's off-the-shelf syndicated reports and robust custom research capabilities. ICON/ICLR-G View source version on Contacts Media contacts: Lisa Henry (GMT time zone)Weber Shandwick (PR adviser)+447785 458203lhenry@ ICON Press Officeiconnews@
Business Wire
16-07-2025
- Business
- Business Wire
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies. The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, operational excellence, and customer satisfaction. Key highlights from the report include: Sponsor satisfaction: For phase 1 research, ICON outperformed all other large CROs claiming the highest overall sponsor satisfaction score of 7.4 on a scale of 1-10. Outstanding operational metrics: ICON outperformed the average performance score of other large CROs in all 17 operational metrics, with a considerable lead differential in 14. These metrics are grouped into three categories of critical service capabilities including delivery metrics (such as adhering to project timelines), staff characteristics (like therapeutic expertise), and accessibility metrics (clinic availability, for example). Robust brand strength: Across the four brand strength performance metrics of familiarity, leadership, reported recent use, and preference, ICON was the only large CRO to improve its scores across the board compared to ISR's 2024 iteration of this research, with the largest gains in leadership and preference. Consistency of excellence: For six consecutive years, ICON has outperformed the weighted average performance scores of the other large CROs in phase 1 clinical trials, demonstrating sustained excellence and reliability. 'ICON's strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally,' said Steve Cutler, CEO. 'Our consistent leadership in phase 1 clinical trials is a testament to our ability to meet and exceed client expectations, deliver high-quality outcomes, and advance breakthroughs in early-phase development.' The benchmarking report used a rigorous methodology to ensure results reflected ICON's true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance of role and responsibility, and mandated a recent interaction with a CRO. The survey data was collected in Q4 2024. For more information, please visit About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: About ISR Market Research: ISR utilises primary research methodologies to offer novel insights into the drug development industry. As an independent market research partner focusing on the life sciences space, ISR helps clients make data-informed decisions with specificity and precision that generalist firms can't match. ISR's analysts are industry experts in their own right with over 15 years of experience in this niche. They also diligently curate membership for ISR's Life Science Panel of respondents. Panel members are from a wide spectrum of geographies and job levels across a variety of roles & responsibilities, and their valuable experiential data informs both ISR's off-the-shelf syndicated reports and robust custom research capabilities. ICON/ICLR-G
Business Wire
07-07-2025
- Business
- Business Wire
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledging ICON's leadership in the application of innovative AI technologies in the industry, the organisation won the AI Project of the Year Award at the Analytics & AI Awards. The award honoured ICON's secure, enterprise-grade AI Assistant that streamlines work across functions, enabling faster insights, automating tasks, and scaling decision support through large language models (LLMs), with several agents live and thousands of global users onboarded. ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards. This recognition is based on feedback shared by ICON employees in India and reflects the inclusive culture the company strives to foster through its ongoing commitment to creating a workplace where women can thrive, lead, and grow. In Asia Pacific, the company was awarded Best CRO in APAC at the 2025 Asia Pacific Biopharma Excellence Awards. The awards honour outstanding achievements in Asian bioprocessing, logistics, supply chain management, and clinical trials, celebrating current industry leaders while inspiring future innovators. ICON's award recognises the organisation and its employees' outstanding efforts and positive contribution in the APAC region. At the PharmaTimes International Clinical Researcher of the Year awards, recognising the talent and passion of clinical researchers from across the globe, ICON boasted over 30 employees who received gold, silver, and bronze awards or who were nominated as finalists. In recognition of the progress the company has made in sustainability, ICON was included on two TIME Magazine rankings: 'World's Best Companies in Sustainable Growth 2025' and 'World's Most Sustainable Companies 2025'. In the former list, which compiles companies who demonstrate both outstanding financial and environmental performance, ICON featured at number 57 out of 500 companies, and was listed as the highest CRO globally and the second highest Irish-based organisation. In the latter list, which ranks the world's 500 most sustainable companies based on their public commitment to, and progress toward, sustainability targets, ICON was included as one of only four CROs, and one of nine Irish companies. Steve Cutler, CEO, ICON commented: 'These achievements once again recognise the dedication of our employees, who go above and beyond every day to deliver the best value to our customers. This is further reflected in the recognition our teams have received in the AI and sustainability space, and well-earned acknowledgement for how we are driving innovation for the future of clinical research and the planet.' A full list of ICON's industry awards can be viewed at About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: ICON/ICLR-G
Business Wire
23-06-2025
- Business
- Business Wire
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
Any changes to this event and links to the live webcast will be posted on the Investor section of our website under ' Events '. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at
